WO2016016692A1 - Process for preparation of atropine - Google Patents

Process for preparation of atropine Download PDF

Info

Publication number
WO2016016692A1
WO2016016692A1 PCT/IB2014/063628 IB2014063628W WO2016016692A1 WO 2016016692 A1 WO2016016692 A1 WO 2016016692A1 IB 2014063628 W IB2014063628 W IB 2014063628W WO 2016016692 A1 WO2016016692 A1 WO 2016016692A1
Authority
WO
WIPO (PCT)
Prior art keywords
atropine
chloride
tropine
acetyltropoyl
process according
Prior art date
Application number
PCT/IB2014/063628
Other languages
French (fr)
Inventor
Franck Lopes COSTA
Hervé LHERMITTE
Original Assignee
Rouver Investment S.À.R.L
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Rouver Investment S.À.R.L filed Critical Rouver Investment S.À.R.L
Priority to PCT/IB2014/063628 priority Critical patent/WO2016016692A1/en
Publication of WO2016016692A1 publication Critical patent/WO2016016692A1/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D451/00Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof
    • C07D451/02Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof
    • C07D451/04Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof with hetero atoms directly attached in position 3 of the 8-azabicyclo [3.2.1] octane or in position 7 of the 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring system
    • C07D451/06Oxygen atoms
    • C07D451/10Oxygen atoms acylated by aliphatic or araliphatic carboxylic acids, e.g. atropine, scopolamine

Definitions

  • the present invention relates to atropine. More particularly, the present invention relates to processes for preparing atropine and its related salts and hydrates.
  • Atropine is a naturally occurring compound extracted from plants such as Atropa belladonna, Datura stramonium and Duboisia myoporoides. Atropine competitively blocks acetylcholine, a neurotransmitter, from acting on the muscarinic receptors in the body. As a result, atropine dilates the pupils, increases heart rate, and reduces salivation and other secretions. Atropine is used for many medicinal purposes. More common uses include administration before anesthesia to decrease mucus secretions, such as saliva. During anesthesia and surgery, atropine is used to maintain a normal heart rate in certain circumstances.
  • Atropine sulfate a salt of atropine, is also used to block or reverse the adverse effects caused by some medicines and certain types of pesticides.
  • Atropine is also used in ophthalmology.
  • atropine is administered prior to eye examinations to dilate the pupil, and to relieve pain caused by swelling and inflammation of the eye.
  • Atropine used for medical purposes is most commonly administered as atropine or as a pharmaceutically acceptable salt, such as atropine sulfate.
  • synthetic methods for preparing atropine are known, commercial production of atropine is typically accomplished by the extraction of atropine from plants.
  • processes for synthetically producing atropine or atropine sulfate suffer from a number of disadvantages that make the synthesis impractical on a commercial scale. This is primarily due to the inefficiency of the reactions involved.
  • Known methods require, for example, the isolation of intermediates, a large excess of reagents, and/or uncertain quality of the synthesized atropine.
  • the present invention provides for a new, efficient and commercially feasible process for the preparation of atropine and atropine salts.
  • a one pot process for the synthesis of atropine is provided.
  • the process provides a high yield and can be used to prepare commercial scale batches of atropine or atropine salts.
  • the process avoids the additional steps of having to isolate intermediates to complete the process.
  • the process has the advantage of proceeding efficiently, for many of the steps, at ambient temperature.
  • a process for the production of atropine and atropine salts includes
  • acetyltropoyl chloride is prepared by reacting tropic acid (3-hydroxy-2-phenylpropanoic acid) with acetyl chloride and a chlorinating agent in the presence of a catalyst to produce acetyltropoyl chloride.
  • the catalyst used may be dimethylformamide (DMF).
  • the chlorinating agent is oxalyl chloride.
  • the tropine is first reacted with methanesulfonic acid to form tropine methanesulfonate prior to step (b).
  • the tropic acid, acetyl chloride and catalyst are in solution prior to the addition of the chlorinating agent to form an acetyltropoyl chloride solution.
  • the tropine is first reacted with methanesulfonic acid to form tropine methanesulfonate prior to step (b) and the acetyltropoyl chloride solution is contacted with the tropine methanesulfonate.
  • the atropine sulfate is converted back to the base form.
  • the process of the invention provides many advantages over known techniques to synthesize atropine or its salts.
  • the process of the invention requires only stoichiometric amounts of the reagents, so excess reagents are not required and the yields of the reaction are high. Moreover, significant steps in the reaction can be performed at ambient temperature. Finally, the process of the invention is efficient even for kilogram sized batches, making the process ideal for the commercial production of atropine and atropine salts.
  • Scheme 1 illustrates the synthetic route leading to atropine, the compound shown in Formula I.
  • the synthetic route involves reacting tropic acid under appropriate conditions to obtain acetyltropoyl chloride, the compound Formula II. From there, the acetyltropoyl chloride is coupled with tropine (also known as tropanol) to produce atropine (Formula I).
  • tropine also known as tropanol
  • the resulting atropine can optionally be converted to a salt or hydrate form, such as for example, atropine hemisulfate hemihydrate, shown below in Formula III.
  • the reactions of the synthetic processes claimed herein are preferably carried out in suitable solvents which may be readily selected by one of ordinary skill in the art.
  • a given reaction may be carried out in one solvent or a mixture of more than one solvent.
  • suitable solvents for a particular reaction step may be selected. Preferred solvents for specific steps are discussed in more detail below.
  • the reaction of tropic acid to produce atropine is preferably carried out according to Scheme II.
  • tropic acid is added to a reaction vessel with a solvent, preferably dichloromethane, to form a suspension.
  • a stoichiometric amount (approximately) of acetyl chloride is added to the reaction vessel in the presence of a catalyst.
  • reference to a stoichiometric amount means at least a stoichiometric amount.
  • reagents identified as a being present in a stoichiometric amount include an amount in excess of the stoichiometric amount, such as up to 120% of the stoichiometric amount. However, the use of too great an excess of that amount is generally undesirable.
  • the catalyst is DMF (Dimethylformamide) in a substoichiometric amount. More preferably the DMF is present in amount of 0.1 Eq.
  • Oxalyl chloride is subsequently added to the reaction vessel to produce acetyltropoyl chloride.
  • a preferred method for the process of producing acetylpropoyl chloride (Formula II) is shown in more detail in Scheme III below.
  • the acetylpropoyl chloride is coupled with tropine to form atropine.
  • the tropine is first reacted with methanesulfonic acid in a solvent (preferably dichloromethane) to form a tropine methanesulfonate solution.
  • a solvent preferably dichloromethane
  • methanesulfonate is reacted with the acetlytropoyl chloride and then hydrolyzed with an acid, preferably a strong acid and more preferably HC1, to produce atropine.
  • an acid preferably a strong acid and more preferably HC1, to produce atropine.
  • Scheme III shows in detail a preferred method for producing acetylpropoyl chloride in accordance with the invention.
  • Scheme III shows the preferred method, acetylpropoyl, available under a variety of names, can be obtained through other means or synthetic processes. Times shown are approximate. The entire reaction can be performed in a single reaction vessel. Throughout the reaction, dichloromethane (“DCM”) is used as the solvent as it allows the reaction to process at a single condition. The concentrations described are approximate and chosen to achieve a high rate of reaction while allowing the reaction to proceed to completion or near completion. Dichloromethane is preferred but other solvents can be used; non-limiting examples include chloroform or 1,2-dichloroethane.
  • DCM dichloromethane
  • the reaction proceeds in two steps.
  • the tropic acid is first reacted with acetyl chloride, preferably in an amount of 1.2 Eq., in a solvent of dichloromethane (preferably about 3 parts). While acetyl chloride is preferred, the acetyl chloride may be replaced by other O-protective groups such as other esters and carbonates for example.
  • acetyl chloride is preferred, the acetyl chloride may be replaced by other O-protective groups such as other esters and carbonates for example.
  • To the reaction medium approximately 0.1 Eq. of DMF is also added and functions as a catalyst.
  • the reaction proceeds at ambient temperature to produce an intermediate. The intermediate is not, and need not be isolated from the reaction medium before proceeding to the next step of the reaction, and is shown in Scheme III for illustrative purposes only.
  • the inventors have surprisingly found that the reaction proceeds effectively to completion or near completion at ambient temperature. Therefore, heating the reaction medium is not necessary and, it has been found to that heating
  • the intermediate is reacted with oxalyl chloride.
  • the oxalyl chloride is added directly to the medium, preferably in an amount of about 1.2 Eq.
  • the reaction to acetylpropoyl chloride proceeds at ambient temperature and again, heating is not necessary, as the reaction will proceed to completion or near completion without heat.
  • oxalyl chloride is preferred, other chlorinating agents may be used as a substitute or in combination, such as thionyl chloride or phosphoryl chloride for example, or phosgene and derivatives for additional examples.
  • Scheme IV shows in detail a preferred method for coupling the acetylpropoyl chloride (Formula II) with tropine to produce atropine (Formula I) in accordance with the invention.
  • tropine is mixed with about 3 parts of dichloromethane and heated to about 40 °C. About 1 Eq. of methanesulfonic acid is added to the medium. While methanesulfonic acid is preferred, other sulfonic acids may be substituted or used in combination such as toluenesulfonic acid. Other acids may also be used such as hydrochloric acid or hydrobromic acid, for example, but sulfonic acids are preferred. A solution of tropine methanesulfonate is produced.
  • the tropine methanesulfonate need not be isolated from the medium.
  • the tropine methanesulfonate medium (about 1.2 Eq.) is mixed with the acetylpropoyl chloride medium, and then hydrolyzed with a strong acid, preferably HCl, to produce atropine.
  • a strong acid preferably HCl
  • the HCl is 1M and added at a concentration of about 6 parts.
  • the reaction medium is preferably heated to about 35°C.
  • the atropine can optionally be purified by techniques known in the art.
  • the crude atropine is recrystallized in a solvent mixture of heptane and dichloromethane.
  • the atropine can optionally be converted to a salt or hydrate.
  • the atropine is converted to the sulfate hemihydrate salt.
  • Scheme V shows in detail a preferred method for converting atropine to atropine hemisulfate hemihydrate (Formula III).
  • purified atropine is dissolved in a solvent system comprising an organic solvent, water or a mixture thereof.
  • a solvent system comprising an organic solvent, water or a mixture thereof.
  • the solvent system is a water/acetone mixture.
  • the atropine solution is mixed in a solution of Sulfuric acid and pH adjusted to between 5.0 and 6.0 to produce the atropine hemisulfate hemihydrate (Formula III).
  • the atropine atropine hemisufate hemihydrate can be converted back to the base form if desired.
  • 4M NaOH is slowly added until pH > 13 at T ⁇ 20°C.
  • the precipitate is filtered and washed with water then dried to provide atropine base.
  • Other methods known in the art may also be used.
  • a batch size of about 2 kg of atropine sulfate was manufactured from 2.0 kg of tropic acid and 2.0 kg of tropanol.
  • the medium containing acetyltropoyl chloride solution, was transferred to a clean container and stored at room temperature.
  • the medium was then cooled down to 20 °C.
  • the agitation was stopped for a 30 minute decantation and the organic layer was discarded.
  • 2 L of new dichloromethane was added and the medium was stirred for 10 minutes.
  • a second 30 minute decantation was performed and again the organic layer was discarded.
  • the aqueous layer was cooled down to 5 °C and a 4M aqueous solution of sodium hydroxide was added over the course of at least 1 hour until the pH of the solution reached at least 13.
  • a solid precipitate formed while the medium was stirred at 5 °C.
  • the solid was collected by filtration after 2 hours of stirring and then washed with 4 L of distilled water resulting in solid atropine (Formula I)(referred to as crude atropine).
  • the crude atropine was added to 14 L of distilled water to form a suspension.
  • the suspension was stirred at 20 °C for at least 1 hour.
  • the solid atropine was collected by filtration and washed with 5 L of distilled water.
  • the white solid was washed with another 4 L of acetone.
  • the final atropine hemisulfate hemihydrate was dried at 20 °C under vacuum until the acetone content was less than or equal to 5000ppm.
  • the final batch size was about 2 kg and the yield on the conversion to the salt was about 95%.
  • the atropine sulfate can be converted back to the base form if desired.
  • 4M NaOH is slowly added until pH > 13 at T ⁇ 20°C.
  • the precipitate is filtered and washed with water then dried to provide atropine base.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

A process for the production of atropine is provided. The process provides for a new, efficient and commercially feasible synthetic process for the preparation of atropine and atropine salts. In one aspect, a one pot process for the synthesis of atropine is provided. The process provides excellent yield and can be used to prepare commercial 5 scale batches of atropine or atropine salts. The process avoids the additional steps of having to isolate intermediates to complete the process and has the advantage of proceeding efficiently at ambient temperature for many of the steps. The process includes providing acetyltropoyl chloride and reacting the acetyltropoyl chloride with tropine followed by a contact with an acid to form atropine.

Description

PROCESS FOR PREPARATION OF ATROPINE
TECHNICAL FIELD
The present invention relates to atropine. More particularly, the present invention relates to processes for preparing atropine and its related salts and hydrates.
BACKGROUND
Atropine is a naturally occurring compound extracted from plants such as Atropa belladonna, Datura stramonium and Duboisia myoporoides. Atropine competitively blocks acetylcholine, a neurotransmitter, from acting on the muscarinic receptors in the body. As a result, atropine dilates the pupils, increases heart rate, and reduces salivation and other secretions. Atropine is used for many medicinal purposes. More common uses include administration before anesthesia to decrease mucus secretions, such as saliva. During anesthesia and surgery, atropine is used to maintain a normal heart rate in certain circumstances. Atropine sulfate, a salt of atropine, is also used to block or reverse the adverse effects caused by some medicines and certain types of pesticides. Atropine is also used in ophthalmology. In this regard, atropine is administered prior to eye examinations to dilate the pupil, and to relieve pain caused by swelling and inflammation of the eye.
Atropine used for medical purposes is most commonly administered as atropine or as a pharmaceutically acceptable salt, such as atropine sulfate. Although synthetic methods for preparing atropine are known, commercial production of atropine is typically accomplished by the extraction of atropine from plants. Currently known processes for synthetically producing atropine or atropine sulfate suffer from a number of disadvantages that make the synthesis impractical on a commercial scale. This is primarily due to the inefficiency of the reactions involved. Known methods require, for example, the isolation of intermediates, a large excess of reagents, and/or uncertain quality of the synthesized atropine.
Accordingly, there is a need for an improved synthetic process for atropine and its salts. There is a need for a synthetic process for commercial scale production of atropine and atropine salts. SUMMARY
The present invention provides for a new, efficient and commercially feasible process for the preparation of atropine and atropine salts. In one aspect, a one pot process for the synthesis of atropine is provided. The process provides a high yield and can be used to prepare commercial scale batches of atropine or atropine salts. The process avoids the additional steps of having to isolate intermediates to complete the process. In addition, the process has the advantage of proceeding efficiently, for many of the steps, at ambient temperature.
Accordingly, in one aspect a process for the production of atropine and atropine salts is provided. The process includes
(a) providing acetyltropoyl chloride; and
(b) reacting the acetyltropoyl chloride with tropine other necessary reagent or reagents to form atropine.
According to another aspect of the application, there are provided processes for preparing the atropine and salts of atropine, embodiments comprising one or a combination of the following steps or features. In one aspect the acetyltropoyl chloride is prepared by reacting tropic acid (3-hydroxy-2-phenylpropanoic acid) with acetyl chloride and a chlorinating agent in the presence of a catalyst to produce acetyltropoyl chloride. The catalyst used may be dimethylformamide (DMF). In another aspect the chlorinating agent is oxalyl chloride.
In another aspect of the invention the tropine is first reacted with methanesulfonic acid to form tropine methanesulfonate prior to step (b). In another aspect, the tropic acid, acetyl chloride and catalyst are in solution prior to the addition of the chlorinating agent to form an acetyltropoyl chloride solution. In yet another aspect the tropine is first reacted with methanesulfonic acid to form tropine methanesulfonate prior to step (b) and the acetyltropoyl chloride solution is contacted with the tropine methanesulfonate.
In another aspect, the atropine sulfate is converted back to the base form.
The process of the invention provides many advantages over known techniques to synthesize atropine or its salts. The process of the invention requires only stoichiometric amounts of the reagents, so excess reagents are not required and the yields of the reaction are high. Moreover, significant steps in the reaction can be performed at ambient temperature. Finally, the process of the invention is efficient even for kilogram sized batches, making the process ideal for the commercial production of atropine and atropine salts.
These and further aspects and preferred embodiments of the invention are described in the following sections and in the appended claims.
DETAILED DESCRIPTION
In an aspect of the invention, there is provided processes for the preparation of atropine (Formula I), including derivatives thereof such as salts and hydrate forms. The processes can be completed without the isolation of any intermediates. A general preparation of atropine according to embodiments of the present invention proceeds as shown in reaction Scheme 1.
Figure imgf000004_0001
Scheme 1 illustrates the synthetic route leading to atropine, the compound shown in Formula I. The synthetic route involves reacting tropic acid under appropriate conditions to obtain acetyltropoyl chloride, the compound Formula II. From there, the acetyltropoyl chloride is coupled with tropine (also known as tropanol) to produce atropine (Formula I). The resulting atropine can optionally be converted to a salt or hydrate form, such as for example, atropine hemisulfate hemihydrate, shown below in Formula III.
Figure imgf000005_0001
The reactions of the synthetic processes claimed herein are preferably carried out in suitable solvents which may be readily selected by one of ordinary skill in the art. A given reaction may be carried out in one solvent or a mixture of more than one solvent. Depending on the particular reaction step, suitable solvents for a particular reaction step may be selected. Preferred solvents for specific steps are discussed in more detail below. The reaction of tropic acid to produce atropine is preferably carried out according to Scheme II.
Figure imgf000005_0002
In the first step of the process of Scheme II, tropic acid is added to a reaction vessel with a solvent, preferably dichloromethane, to form a suspension. A stoichiometric amount (approximately) of acetyl chloride is added to the reaction vessel in the presence of a catalyst. For the purposes of the invention, reference to a stoichiometric amount means at least a stoichiometric amount. Unless noted otherwise, reagents identified as a being present in a stoichiometric amount include an amount in excess of the stoichiometric amount, such as up to 120% of the stoichiometric amount. However, the use of too great an excess of that amount is generally undesirable. In theory, less than a stoichiometric amount may be used but that will have an impact on the yield. Preferably the catalyst is DMF (Dimethylformamide) in a substoichiometric amount. More preferably the DMF is present in amount of 0.1 Eq. Oxalyl chloride is subsequently added to the reaction vessel to produce acetyltropoyl chloride. A preferred method for the process of producing acetylpropoyl chloride (Formula II) is shown in more detail in Scheme III below.
Returning to Scheme II, the acetylpropoyl chloride is coupled with tropine to form atropine. The tropine is first reacted with methanesulfonic acid in a solvent (preferably dichloromethane) to form a tropine methanesulfonate solution. The tropine
methanesulfonate is reacted with the acetlytropoyl chloride and then hydrolyzed with an acid, preferably a strong acid and more preferably HC1, to produce atropine.
Scheme III shows in detail a preferred method for producing acetylpropoyl chloride in accordance with the invention. Although, Scheme III shows the preferred method, acetylpropoyl, available under a variety of names, can be obtained through other means or synthetic processes. Times shown are approximate. The entire reaction can be performed in a single reaction vessel. Throughout the reaction, dichloromethane ("DCM") is used as the solvent as it allows the reaction to process at a single condition. The concentrations described are approximate and chosen to achieve a high rate of reaction while allowing the reaction to proceed to completion or near completion. Dichloromethane is preferred but other solvents can be used; non-limiting examples include chloroform or 1,2-dichloroethane.
Figure imgf000006_0001
to ®c¾
The reaction proceeds in two steps. The tropic acid is first reacted with acetyl chloride, preferably in an amount of 1.2 Eq., in a solvent of dichloromethane (preferably about 3 parts). While acetyl chloride is preferred, the acetyl chloride may be replaced by other O-protective groups such as other esters and carbonates for example. To the reaction medium, approximately 0.1 Eq. of DMF is also added and functions as a catalyst. The reaction proceeds at ambient temperature to produce an intermediate. The intermediate is not, and need not be isolated from the reaction medium before proceeding to the next step of the reaction, and is shown in Scheme III for illustrative purposes only. The inventors have surprisingly found that the reaction proceeds effectively to completion or near completion at ambient temperature. Therefore, heating the reaction medium is not necessary and, it has been found to that heating may prevent the reaction from completion.
After completion of the acetylation reaction, the intermediate is reacted with oxalyl chloride. The oxalyl chloride is added directly to the medium, preferably in an amount of about 1.2 Eq. The reaction to acetylpropoyl chloride proceeds at ambient temperature and again, heating is not necessary, as the reaction will proceed to completion or near completion without heat. While oxalyl chloride is preferred, other chlorinating agents may be used as a substitute or in combination, such as thionyl chloride or phosphoryl chloride for example, or phosgene and derivatives for additional examples.
Scheme IV shows in detail a preferred method for coupling the acetylpropoyl chloride (Formula II) with tropine to produce atropine (Formula I) in accordance with the invention.
Figure imgf000007_0001
Figure imgf000007_0002
In a reactor tropine is mixed with about 3 parts of dichloromethane and heated to about 40 °C. About 1 Eq. of methanesulfonic acid is added to the medium. While methanesulfonic acid is preferred, other sulfonic acids may be substituted or used in combination such as toluenesulfonic acid. Other acids may also be used such as hydrochloric acid or hydrobromic acid, for example, but sulfonic acids are preferred. A solution of tropine methanesulfonate is produced.
The tropine methanesulfonate need not be isolated from the medium. The tropine methanesulfonate medium (about 1.2 Eq.) is mixed with the acetylpropoyl chloride medium, and then hydrolyzed with a strong acid, preferably HCl, to produce atropine. (Formula I). Preferably the HCl is 1M and added at a concentration of about 6 parts. The reaction medium is preferably heated to about 35°C.
The atropine can optionally be purified by techniques known in the art. In one embodiment, the crude atropine is recrystallized in a solvent mixture of heptane and dichloromethane. The atropine can optionally be converted to a salt or hydrate. In one embodiment, the atropine is converted to the sulfate hemihydrate salt.
Scheme V shows in detail a preferred method for converting atropine to atropine hemisulfate hemihydrate (Formula III).
Figure imgf000008_0001
im s iKssssSste te-ss viSi &¾«
Preferably, purified atropine is dissolved in a solvent system comprising an organic solvent, water or a mixture thereof. Preferably the solvent system is a water/acetone mixture. The atropine solution is mixed in a solution of Sulfuric acid and pH adjusted to between 5.0 and 6.0 to produce the atropine hemisulfate hemihydrate (Formula III).
Optionally, the atropine atropine hemisufate hemihydrate can be converted back to the base form if desired. In one embodiment, 4M NaOH is slowly added until pH > 13 at T <20°C. The precipitate is filtered and washed with water then dried to provide atropine base. Other methods known in the art may also be used. EXAMPLES
Certain specific aspects and embodiments of the present disclosure will be explained in more detail with reference to the following examples, which are provided solely for purposes of illustration and are not to be construed as limiting the scope of the disclosure in any manner. A batch size of about 2 kg of atropine sulfate was manufactured from 2.0 kg of tropic acid and 2.0 kg of tropanol.
Synthesis crude atropine
In a reactor 2.0 kg of tropic acid was added to 6 L of dichloromethane and a suspension was formed. The suspension was stirred at 40 Hz at 25 °C. To the suspension 0.1 Eq. of DMF was added. Acetyl chloride was slowly added over the course of at least 30 minutes. The medium was stirred at 25 °C for 3 hours. 1.2 Eq. of oxalyl chloride (1.84kg) was then added to the medium over the course of at least 1 hour. The medium was stirred for 2 hours at 25 °C.
The medium, containing acetyltropoyl chloride solution, was transferred to a clean container and stored at room temperature.
In a reactor 2.0 kg of tropine was added to 6 L of dichloromethane to form a solution. The solution was stirred until it reached 35 °C. 1.0 Eq. of methane sulfonic acid (1.39kg) was added over the course of at least 30 minutes. The medium was stirred for 10 min at 35 °C to form a tropine methanesulfonate solution.
The acetyltropoyl chloride solution was then transferred to the tropine
methanesulfonate solution and the resulting solution was stirred at reflux for at least 18 hours. The reaction medium was then cooled down to 35 °C. 12 L of a 1M solution of hydrochloric acid was added producing a biphasic mixture. The biphasic mixture was stirred for at least 24 hours at 35 °C resulting in an aqueous layer containing atropine.
The medium was then cooled down to 20 °C. The agitation was stopped for a 30 minute decantation and the organic layer was discarded. 2 L of new dichloromethane was added and the medium was stirred for 10 minutes. A second 30 minute decantation was performed and again the organic layer was discarded.
The aqueous layer was cooled down to 5 °C and a 4M aqueous solution of sodium hydroxide was added over the course of at least 1 hour until the pH of the solution reached at least 13. A solid precipitate formed while the medium was stirred at 5 °C. The solid was collected by filtration after 2 hours of stirring and then washed with 4 L of distilled water resulting in solid atropine (Formula I)(referred to as crude atropine).
In a reactor the crude atropine was added to 14 L of distilled water to form a suspension. The suspension was stirred at 20 °C for at least 1 hour. The solid atropine was collected by filtration and washed with 5 L of distilled water.
The crude atropine was dried under vacuum at 60 °C until water content was below 1.0% as measured by Karl Fischer titration. The yield was about 75%. Crystallization of crude atropine
In a reactor the crude atropine (about 2.9kg) was added to dichloromethane (about 5.8 L) (2 L for every kg of crude atropine) to form a suspension. The suspension was stirred until it reached 30 °C. To the suspension, heptane (about 20L) (7 L of heptane for every L of dichloromethane) was added over the course of at least 1 hour. The medium was cooled to 5 °C and stirred at this temperature for at 1 hour allowing the atropine to crystallize. The crystallized atropine was collected by filtration and washed with heptane (2L of heptane for every L of dichloromethane). The crystallized atropine was dried under vacuum at 60 °C until it measured below 2.0% by loss on drying. The yield of this process was about 90%.
Preparation of the sulfate hemihydrate salt of atropine
In a reactor 2 kg of crystallized atropine was added to 20 L of acetone and 60 mL of microbio water (bacteria free water) to form a solution. The solution was stirred and heated to 50 °C. The medium was then filtered on a clarification membrane. The medium was then cooled to 30 °C. Separately, a sulfuric acid solution was prepared by adding 372 mL of H2S04 (95%) to 1680 mL of microbio water. The sulfuric acid solution was added over the course of 1 hour so that the pH was adjusted to between 5.0 and 6.0. The medium was then cooled down to 15 °C and the solid (atropine hemisulfate hemihydrate, (Formula III)) was collected by filtration. The white solid was washed with another 4 L of acetone. The final atropine hemisulfate hemihydrate was dried at 20 °C under vacuum until the acetone content was less than or equal to 5000ppm. The final batch size was about 2 kg and the yield on the conversion to the salt was about 95%.
The atropine sulfate can be converted back to the base form if desired. In one embodiment, 4M NaOH is slowly added until pH > 13 at T <20°C. The precipitate is filtered and washed with water then dried to provide atropine base.
Unless defined otherwise, all technical terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this invention belongs. Any methods and materials similar or equivalent to those described herein also can be used in the practice or testing of the present disclosure.
It must be noted that as used herein and in the appended claims, the singular forms
"a", "and", and "the" include plural references unless the context clearly dictates otherwise.
While the present disclosure has been described with reference to the specific embodiments thereof, it should be understood by those skilled in the art that various changes may be made and equivalents may be substituted without departing from the true spirit and scope of the invention. In addition, many modifications may be made to adapt a particular situation, material, composition of matter, process, process step or steps, to the objective spirit and scope of the present disclosure. All such modifications are intended to be within the scope of the claims appended hereto.

Claims

1. A process for the preparation of atropine (Formula I), comprising the steps of:
Figure imgf000012_0001
(a) reacting tropic acid (3-hydroxy-2-phenylpropanoic acid) with acetyl chloride and a chlorinating agent in the presence of a catalyst to produce acetyltropoyl chloride (Formula II);
N» orm la: II
(b) reacting the acetyltropoyl chloride with tropine, followed by a contact with an acid to produce atropine.
2. A process according to claim 1, wherein the catalyst used in step (a) is dimethylformamide (DMF).
3. A process according to claim 1, wherein the chlorinating agent is oxalyl chloride.
4. A process according to claim 1, wherein the tropine is first reacted with methanesulfonic acid to form tropine methanesulfonate prior to step (b).
5. A process according to claim 1, wherein the tropic acid, acetyl chloride and catalyst are in solution prior to the addition of the chlorinating agent to form an acetyltropoyl chloride solution.
6. A process according to claim 4, wherein the acetyl chloride is added in a stoichiometric amount.
7. A process according to claim 5, wherein the tropine is first reacted with methanesulfonic acid to form tropine methanesulfonate prior to step (b) and the acetyltropoyl chloride solution is contacted with the tropine methanesulfonate.
8. A process according to claim 2, wherein the reaction to form acetyltropoyl chloride is performed at ambient temperature .
9. A process according to claim 1 further comprising the step of converting the atropine to atropine hemisulfate hemihydrate.
10. A process for the preparation of atropine sulfate (Formula III) comprising the steps of:
Figure imgf000013_0001
(a) provi la II; and
Figure imgf000013_0002
(b) reacting the acetyltropoyl chloride with tropine, followed by a contact with an acid to form atropine; and
(c) converting the atropine to atropine sulfate.
11. A process according to claim 1, wherein the acetyltropoyl chloride is provided by reacting tropic acid (3-hydroxy-2-phenylpropanoic acid) with acetyl chloride and a chlorinating agent in the presence of a catalyst.
12. A process according to claim 1 1, wherein the catalyst used is dimethylformamide (DMF).
13. A process according to claim 1 1, wherein the chlorinating agent is oxalyl chloride.
14. A process according to claim 1 1, wherein the tropine is first reacted with methanesulfonic acid to form tropine methanesulfonate prior to step (b).
15. A process according to claim 1 1, wherein the tropic acid, acetyl chloride and catalyst are in solution prior to the addition of the chlorinating agent to form an acetyltropoyl chloride solution.
16. A process according to claim 15, wherein the acetyl chloride is added in a stoichiometric amount of the tropic acid.
17. A process according to claim 15, wherein the tropine is first reacted with methanesulfonic acid to form tropine methanesulfonate prior to step (b) and the acetyltropoyl chloride solution is contacted with the tropine methanesulfonate.
18. A process according to claim 12, wherein the reaction to form acetyltropoyl chloride is performed at ambient temperature.
19. A process for the preparation of atropine (Formula I), comprising the steps of:
Figure imgf000014_0001
(a) reacting tropic acid (3-hydroxy-2-phenylpropanoic acid) with acetyl chloride and a chlorinating agent in the presence of a catalyst to produce acetyltropoyl chloride (Formula II);
Figure imgf000014_0002
(c) reacting the acetyltropoyl chloride with tropine, and contact with an acid to form atropine.
PCT/IB2014/063628 2014-08-01 2014-08-01 Process for preparation of atropine WO2016016692A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
PCT/IB2014/063628 WO2016016692A1 (en) 2014-08-01 2014-08-01 Process for preparation of atropine

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/IB2014/063628 WO2016016692A1 (en) 2014-08-01 2014-08-01 Process for preparation of atropine

Publications (1)

Publication Number Publication Date
WO2016016692A1 true WO2016016692A1 (en) 2016-02-04

Family

ID=51743494

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IB2014/063628 WO2016016692A1 (en) 2014-08-01 2014-08-01 Process for preparation of atropine

Country Status (1)

Country Link
WO (1) WO2016016692A1 (en)

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20190102899A (en) * 2018-02-27 2019-09-04 명문바이오 주식회사 Method for preparing atropine
CN111253389A (en) * 2020-03-17 2020-06-09 合肥创新医药技术有限公司 Synthetic method of atropine and atropine sulfate
CN112592312A (en) * 2020-12-23 2021-04-02 无锡济煜山禾药业股份有限公司 Preparation method of tropicamide
CN114557955A (en) * 2018-09-25 2022-05-31 沈阳兴齐眼科医院有限公司 Pharmaceutical composition, preparation method and application thereof
CN116396160A (en) * 2023-06-05 2023-07-07 烟台万润药业有限公司 Method for preparing tropine acid and method for preparing atropine sulfate by using tropine acid

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014102829A1 (en) * 2012-12-31 2014-07-03 Mylan Laboratories Ltd. Crystalline atropine sulfate

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014102829A1 (en) * 2012-12-31 2014-07-03 Mylan Laboratories Ltd. Crystalline atropine sulfate

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
ATKINSON E R; MCRITCHIE TICKNOR D D; HARRIS L S; ET AL.: "Parasympatholytic (anticholinergic) esters of the isomeric 2-tropanols. 2. Non-glycolates", JOURNAL OF MEDICINAL CHEMISTRY, vol. 26, no. 12, 1983, pages 1772 - 1775, XP002733877, ISSN: 0022-2623 *
SCHMIDT G C; ELING T E; DRACH J C: "Synthesis of tropine-labeled atropine. I. Micro methods for the synthesis of tropine and for its esterification with tropic acid.", JOURNAL OF PHARMACEUTICAL SCIENCES, vol. 56, no. 2, 1 February 1967 (1967-02-01), WASHINGTON, US, pages 215 - 221, XP055158885, ISSN: 0022-3549 *

Cited By (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20190102899A (en) * 2018-02-27 2019-09-04 명문바이오 주식회사 Method for preparing atropine
KR102595725B1 (en) * 2018-02-27 2023-10-30 명문바이오 주식회사 Method for preparing atropine
CN114557955A (en) * 2018-09-25 2022-05-31 沈阳兴齐眼科医院有限公司 Pharmaceutical composition, preparation method and application thereof
CN111253389A (en) * 2020-03-17 2020-06-09 合肥创新医药技术有限公司 Synthetic method of atropine and atropine sulfate
CN112592312A (en) * 2020-12-23 2021-04-02 无锡济煜山禾药业股份有限公司 Preparation method of tropicamide
WO2022134316A1 (en) * 2020-12-23 2022-06-30 无锡济煜山禾药业股份有限公司 Preparation method for tropicamide
CN116396160A (en) * 2023-06-05 2023-07-07 烟台万润药业有限公司 Method for preparing tropine acid and method for preparing atropine sulfate by using tropine acid
CN116396160B (en) * 2023-06-05 2023-08-22 烟台万润药业有限公司 Method for preparing tropine acid and method for preparing atropine sulfate by using tropine acid

Similar Documents

Publication Publication Date Title
US11472773B2 (en) Salt of omecamtiv mecarbil and process for preparing salt
WO2016016692A1 (en) Process for preparation of atropine
NO153082B (en) APPARATUS FOR STAPPING A WRINKED RODFORM SHEET
US10870654B2 (en) Pharmaceutically acceptable salts and polymorphic forms of hydrocodone benzoic acid enol ester and processes for making same
HUE029401T2 (en) Process for preparing tiotropium bromide
US9914692B2 (en) Procedure for the preparation of 4-phenyl butyrate and uses thereof
SG192858A1 (en) Novel compounds as histamine h3 receptor ligands
US20210139462A1 (en) Process for the preparation of a sulfonamide structured kinase inhibitor
CN111253389A (en) Synthetic method of atropine and atropine sulfate
JP5826371B2 (en) Method for producing pemetrexed salt
CN101993447A (en) Method for synthesizing Prasugrel artificially
US20150239909A1 (en) Process for the preparation of (1s,4s,5s)-4-bromo-6-oxabicyclo[3.2.1]octan-7-one
KR101485418B1 (en) A synthetic method of high purity mirtazapine
JP2011519840A (en) Preparation of 1,7&#39;-dimethyl-2&#39;-propyl-2,5&#39;-bi-1H-benzimidazole
US3705150A (en) Process for the preparation of 21-deoxy - 21-n-(n&#39;-methylpiperazinyl)-prednisolone and salts thereof
CN114436880A (en) Preparation method of iopromide intermediate
CN111662351B (en) New octreolone type sapogenin derivative and application thereof in preparation of drug-resistant bacteria resistant drugs
CA2548507A1 (en) A process for the resolution of nefopam
CN108623608B (en) Preparation method of zabucfloxacin intermediate
AU2008298402B2 (en) Method for producing N-methacryloyl-4-cyano-3-trifluoromethylaniline
CN107778307B (en) Preparation method of central alpha 2 adrenoreceptor agonist
US20180111938A1 (en) Synthesis of Intermediates Used in the Manufacture of Anti-HIV Agents
WO2019207494A1 (en) Method for the preparation of pimavanserin base
CN115108939A (en) Intermediate of trans-4- [ (2-amino-3, 5-dibromo benzyl) amino ] -adamantan-1-ol and preparation method thereof
JP4799872B2 (en) Quaternary ammonium compound, method for producing the same, and therapeutic agent for cerebrovascular disorder

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 14786279

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 14786279

Country of ref document: EP

Kind code of ref document: A1